Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study

医学 微小残留病 内科学 免疫分型 胃肠病学 淋巴细胞白血病 白血病 免疫学 流式细胞术
作者
Brent L. Wood,Meenakshi Devidas,Ryan J. Summers,Zhiguo Chen,Barbara L. Asselin,Karen R. Rabin,Patrick A. Zweidler‐McKay,Naomi J. Winick,Michael J. Borowitz,William L. Carroll,Elizabeth A. Raetz,Mignon L. Loh,Stephen P. Hunger,Kimberly P. Dunsmore,David T. Teachey,Stuart S. Winter
出处
期刊:Blood [Elsevier BV]
卷期号:142 (24): 2069-2078 被引量:21
标识
DOI:10.1182/blood.2023020678
摘要

Abstract The early thymic precursor (ETP) immunophenotype was previously reported to confer poor outcome in T-cell acute lymphoblastic leukemia (T-ALL). Between 2009 and 2014, 1256 newly diagnosed children and young adults enrolled in Children’s Oncology Group (COG) AALL0434 were assessed for ETP status and minimal residual disease (MRD) using flow cytometry at a central reference laboratory. The subject phenotypes were categorized as ETP (n = 145; 11.5%), near-ETP (n = 209; 16.7%), or non-ETP (n = 902; 71.8%). Despite higher rates of induction failure for ETP (6.2%) and near-ETP (6.2%) than non-ETP (1.2%; P < .0001), all 3 groups showed excellent 5-year event-free survival (EFS) and overall survival (OS): ETP (80.4% ± 3.9% and 86.8 ± 3.4%, respectively), near-ETP (81.1% ± 3.3% and 89.6% ± 2.6%, respectively), and non-ETP (85.3% ± 1.4% and 90.0% ± 1.2%, respectively; P = .1679 and P = .3297, respectively). There was no difference in EFS or OS for subjects with a day-29 MRD <0.01% vs 0.01% to 0.1%. However, day-29 MRD ≥0.1% was associated with inferior EFS and OS for patients with near-ETP and non-ETP, but not for those with ETP. For subjects with day-29 MRD ≥1%, end-consolidation MRD ≥0.01% was a striking predictor of inferior EFS (80.9% ± 4.1% vs 52.4% ± 8.1%, respectively; P = .0001). When considered as a single variable, subjects with all 3 T-ALL phenotypes had similar outcomes and subjects with persistent postinduction disease had inferior outcomes, regardless of their ETP phenotype. This clinical trial was registered at AALL0434 as #NCT00408005.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jxzhou完成签到 ,获得积分10
1秒前
2秒前
Bob完成签到,获得积分10
2秒前
幽默梦山完成签到,获得积分10
3秒前
脑洞疼应助kyt采纳,获得10
3秒前
3秒前
木棉发布了新的文献求助10
5秒前
6秒前
子健完成签到,获得积分10
7秒前
幽默梦山发布了新的文献求助10
7秒前
陈_研完成签到,获得积分20
8秒前
9秒前
饼子完成签到 ,获得积分10
9秒前
李健应助feilei采纳,获得10
10秒前
ma发布了新的文献求助10
10秒前
zzz完成签到,获得积分10
11秒前
zhentg完成签到,获得积分0
14秒前
苗一夫完成签到,获得积分20
15秒前
于其言发布了新的文献求助20
15秒前
CodeCraft应助哈哈哈哈哈采纳,获得10
17秒前
fanfan完成签到,获得积分10
19秒前
纯爱完成签到,获得积分10
20秒前
阿元发布了新的文献求助10
20秒前
温暖哈密瓜完成签到 ,获得积分10
22秒前
花栗鼠完成签到,获得积分10
22秒前
飞快的羊青完成签到,获得积分10
22秒前
我不爱池鱼应助孙五六采纳,获得10
22秒前
科研牛马完成签到,获得积分10
25秒前
ylyn完成签到,获得积分10
26秒前
于其言完成签到,获得积分10
27秒前
28秒前
Liu发布了新的文献求助10
30秒前
玛玛卡卡发布了新的文献求助10
31秒前
LYSM应助小飞侠采纳,获得10
31秒前
思源应助ylyn采纳,获得10
32秒前
许言发布了新的文献求助30
32秒前
聪慧芷巧应助阔达博采纳,获得10
33秒前
38秒前
量子星尘发布了新的文献求助10
38秒前
小豪号完成签到,获得积分10
41秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A new approach to the extrapolation of accelerated life test data 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3954521
求助须知:如何正确求助?哪些是违规求助? 3500524
关于积分的说明 11099808
捐赠科研通 3230997
什么是DOI,文献DOI怎么找? 1786258
邀请新用户注册赠送积分活动 869904
科研通“疑难数据库(出版商)”最低求助积分说明 801717